Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014

Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression

Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments

Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy®) in Advanced Melanoma

Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer

Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer

Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting

Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase l/ll Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer